key: cord-0903132-u0lyk8e5
authors: Cordes, A. K.; Rehrauer, W. M.; Accola, M. M.; Woelk, B.; Hilfrich, B.; Heim, A.
title: Fully automated detection and differentiation of pandemic and endemic coronaviruses (NL63, 229E, HKU1, OC43 and SARS-CoV-2) on the Hologic Panther Fusion
date: 2020-09-02
journal: nan
DOI: 10.1101/2020.08.31.20185074
sha: bf788216fd3498ff7ec393988ac8cf89ad356fb3
doc_id: 903132
cord_uid: u0lyk8e5

The Hologic Panther Fusion (PF) platform provides fully automated CE marked diagnostics for respiratory viruses, including recently SARS-coronavirus 2 by a transcription mediated amplification (TMA) assay, but not for the endemic human coronaviruses (hCoV). Therefore, a laboratory developed multiplexed RT-PCR protocol (LDT) that detects and differentiates the four hCoV NL63, 229E, HKU1 and OC43 was adapted on the PF. The novel CE marked Aptima SARS-CoV-2 TMA and the LDT for hCoV were validated with 321 diagnostic specimens from the upper and lower respiratory tract in comparison to two SARS-CoV-2 RT-PCRs (PF E-gene LDT and genesig RT-PCR, 157 specimens) or the R-GENE hCoV / hParaFlu RT-PCR (164 specimens), respectively. For the endemic hCoV, results were 96.3% concordant with two specimens discordantly positive in the PF and four specimens discordantly positive in the R-GENE assay. All discordantly positive samples had Ct values between 33 and 39. The PF hCoV LDT identified 23 hCoV positive specimens as NL63, 15 as 229E, 15 as HKU1 and 25 as OC43. The Aptima SARS-CoV-2 TMA gave 99.4 % concordant results compared to the consensus results with a single specimen discordantly positive. Moreover, 36 samples from proficiency testing panels were detected and typed correctly by both novel methods. In conclusion, the SARS-CoV-2 TMA and the LDT for hCoV enhanced the diagnostic spectrum of the PF for all coronaviruses circulating globally for a multitude of diagnostic materials from the upper and lower respiratory tract.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint respiratory viruses. For comparison, the Hologic Panther Fusion (PF) system provides a panel 65 of three CE marked and FDA cleared multiplex real-time PCRs that cover influenza virus A/B 66 (Flu A/B), respiratory syncytial virus (RSV), parainfluenza virus 1-4 (ParaFlu), human 67 metapneumovirus (hMPV), adenovirus (AdV) and rhinovirus (RhV) and can be performed 68 according to the individual diagnostic request. These assays were validated for samples from 69 the lower respiratory tract in a previous study (22) . 70 Recently, a TMA based assay for SARS-CoV-2 became available for the Panther (Aptima 71 SARS-CoV-2 assay) (23) which is CE marked and FDA cleared for emergency use (EUA) for 72 samples from the upper respiratory tract (nasopharyngeal swabs, washes and aspirates; nasal 73 swabs and aspirates, oropharyngeal swabs). In addition, an early laboratory developed real 74 time PCR for the SARS-CoV E-gene (24) and a FDA EUA cleared RT-PCR for the SARS-75 CoV-2 Orf1ab which is only available in the U.S. (25), can be applied on the PF platform.

However, the endemic human coronaviruses were not yet covered. As these are responsible 77 for about 13-19.7 % of the respiratory infections (2, 26), we used the PF Open Access tool to 78 establish and validate a multiplexed laboratory developed test (LDT) that detects and 79 differentiates the four endemic hCoVs 229E, OC43, NL63 and HKU1. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https: //doi.org/10.1101 //doi.org/10. /2020 

Proficiency testing panels 83 36 proficiency testing specimens provided by Instand (Düsseldorf, Germany) in the years is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint ethical committee "Ethikkommission der Medizinischen Hochschule Hannover", 19th of 105 September, 2019 and 6th of May 2020).

Swabs were re-suspended in 1.5 ml PBS -. Liquid samples (lavages and secretions) were 108 loaded without prior processing of the sample. However, viscous samples were diluted 1:2 in 109 PBSto avoid clotting in the pipette tip. For testing on the PF, 500 µl of the specimen (patient is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint analysis settings in the PF software were set as following: The analysis start cycle was set at 129 10, the baseline correction was enabled and the slope limit was set at 25. As a positivity 130 criteria the Ct threshold in the channels 1 (FAM for 229E), 2 (HEX for NL63) and 3 (ROX 131 for HKU1) was set to 200 RFU, in channel 4 (Quasar 670 for OC43) to 300 RFU and in 132 channel 5 (Quasar 705 for IC) to 1000 RFU. The crosstalk correction was set to 1 % for the 133 combination of emitter channel 1 and receiver channel 2, as well as the combination of 

The SARS-CoV-2 E gene RT-PCR was performed with the Open Access tool on the Panther 141 Fusion as described previously (24).

Nucleic acid extraction was performed on a QIAcube using the DNeasy blood kit (QIAGEN, 144 Hilden, Germany). Of the eluate, 10 µl were tested by the hCoV / hParaFlu R-GENE assay 145 (bioMérieux, Marcy-l'Étoile, France) on an ABI 7500 sequence detection system (ABI, Foster 146 City, CA, U.S.). This assay has been validated previously for multiple types of respiratory 147 specimens.

Nucleic acid extraction was performed on a QIAcube using the DNeasy blood kit (QIAGEN, 150 Hilden, Germany). Of the eluate, 10 µL were tested by the genesig coronavirus COVID-19 151 . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint Real-Time PCR assay (Primerdesign, Chandler's Ford, UK) on an ABI 7500 sequence was available. Therefore, a patient sample that had been tested highly positive in the hCoV / 160 ParaFlu R-GENE assay was used for estimating the amplification efficiency.

For the Aptima SARS-CoV-2, the limit of detection (LOD) was determined from half 162 logarithmic serial dilutions. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint

The LOD of the Aptima SARS-CoV-2 TMA was 288 copies/ml (95 % confidence interval 177 191 -755 copies/ml) determined as the 95 % probability of detection. In case of 229E, NL63, 178 OC43 and HKU1 the LODs were not determined due to the limited availability of quantified 179 reference materials but amplification efficiencies of PCR were calculated. Amplification is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. SARS-CoV-2 RNA due to its very low LOD. In our hands, LOD was determined to be 288 241 copies/ml, whereas others had a 100 % detection rate at 83 copies/ml also using quality is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint control material from Seracare but with only 20 replicates tested (29). Nevertheless, the LOD 243 of the Aptima SARS-CoV-2 assay was even lower than the LOD of the E-gene RT-PCR on 244 the PF (315 copies/ml). Both assays, run automatized on the PF from samples that have been 245 processed identically before having been loaded onto the platform. On the PF, 360 µl of the 246 sample are pipetted for both assays, however, only 10 % of the extracted nucleic acid is used 247 for the PCR reaction, while in the TMA the total volume is applied. Although highly 248 sensitive, the Aptima SARS-CoV-2 assay is highly specific and does not cross-react SARS- is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint positives. Another limitation of the study was that HKU1 was not included in the panel of 269 proficiency testing specimens probably because HKU1 cannot be grown in cell culture easily 270 (37). As the R-GENE assay does not differentiate the endemic hCoV, we could not confirm 271 that a sample positive for HKU1 in the PF LDT truly contains HKU1 RNA but 13 of 15 272 samples positive for HKU1 were at least confirmed as hCoV positive in the R-GENE assay.

Moreover, the primer and probe sequences for HKU1 (and all other hCoVs) that had 274 previously been published (27) were reanalyzed on specificity using Nucleotide Blast (NCBI 275 PubMed). As no homology of the primer and probe sequences with another than the intended 276 corresponding hCoV sequence was detected, we presume classification to be correct. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020 . . https://doi.org/10.1101 /2020 is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint Supplementary table 3: Those samples that were found to be positive in at least two out of three assays were declared as consensus positive. For negative samples the criteria was implemented respectively. . CC-BY-NC-ND 4.0 International license It is made available under a perpetuity.

is the author/funder, who has granted medRxiv a license to display the preprint in (which was not certified by peer review) preprint

The copyright holder for this this version posted September 2, 2020. . https://doi.org/10.1101/2020.08.31.20185074 doi: medRxiv preprint

2020. The natural history and transmission potential of asymptomatic 346 SARS-CoV-2 infection

Epidemiology of COVID-19 Among 348 Children in China

Clinical presentation and virological assessment of 352 hospitalized cases of coronavirus disease 2019 in a travel-associated transmission cluster

Comparison 355 of real-time PCR assays with fluorescent-antibody assays for diagnosis of respiratory virus 356 infections in children

Detection of respiratory viruses by molecular methods

Comparison of the Luminex xTAG RVP Fast assay and the Idaho Technology FilmArray 361 RP assay for detection of respiratory viruses in pediatric patients at a cancer hospital

Analytical and Clinical 396 Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection

False-Negative Nasopharyngeal Swab

Assays in Typical COVID-19: Role of Ultra-low-dose Chest CT and Bronchoscopy in Diagnosis

Detection of SARS-CoV-2 by bronchoscopy 403 after negative nasopharyngeal testing: Stay vigilant for COVID-19

Usefulness of bronchoalveolar lavage in 407 the management of patients presenting with lung infiltrates and suspect COVID-19-408 associated pneumonia: A case report

Human 410 coronavirus NL63 employs the severe acute respiratory syndrome coronavirus receptor for 411 cellular entry

New human coronavirus, HCoV-NL63, 413 associated with severe lower respiratory tract disease in Australia

Selective and cross-reactive SARS-CoV-2 T cell epitopes in unexposed